Affymax, (FRA:A5Y) Common Stock : €0.03 Mil (As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Affymax, Common Stock?

Affymax,'s quarterly common stock stayed the same from Dec. 2013 (€0.03 Mil) to Mar. 2014 (€0.03 Mil) and stayed the same from Mar. 2014 (€0.03 Mil) to Jun. 2014 (€0.03 Mil).

Affymax,'s annual common stock increased from Dec. 2011 (€0.03 Mil) to Dec. 2012 (€0.03 Mil) but then declined from Dec. 2012 (€0.03 Mil) to Dec. 2013 (€0.03 Mil).

Affymax, Common Stock Historical Data

The historical data trend for Affymax,'s Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax, Common Stock Chart

Affymax, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Common Stock

Get a 7-Day Free Trial

0.02

0.03

Affymax, Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Common Stock	Get a 7-Day Free Trial															0.03	0.03	0.03	0.03	0.03

Affymax, Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Affymax, (FRA:A5Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020

Website

http://www.affymax.com

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines